title: Testosterone therapy: treatment of metabolic disturbances in heart failure.
abstract: Heart failure (HF) is a complex progressive multisystem disease state with significant morbidity and mortality, which is not solely defined by pathology of the cardiovascular system but also is influenced by neurohormonal regulatory adjustments, peripheral cytokines, as well as hormonal and musculoskeletal dysfunction. Recent attention to the catabolic state found in patients with chronic heart failure has sparked interest in new potential targets for medical therapy. In particular, as many as 26% to 37% of men affected with HF have been found to be testosterone deficient. The severity of androgen deficiency has been shown to correlate with symptoms, functional class, and prognosis in patients with heart failure. Testosterone supplementation has been an accepted therapy in hypogonadal men with fatigue, muscle wasting, and sexual dysfunction for some time. Patients with severe HF show a similar constellation of symptoms and hypothetically would benefit from androgen replacement. Recent clinical studies have confirmed that functional, biochemical, and cardiopulmonary status in patients with HF have significant improvements when treated with testosterone supplementation. Symptomatic improvements may be obtainable in hypogonadal patients with HF who receive supplemental testosterone. This review seeks to outline the cardiovascular and peripheral effects of testosterone supplementation in patients with chronic HF.
authors.affiliation: Cedars-Sinai Heart Institute, Comprehensive Transplant Program, Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
authors.forename: Jesse J
authors.initials: JJ
authors.lastname: Naghi
authors.forename: Kiran J
authors.initials: KJ
authors.lastname: Philip
authors.forename: Deanna
authors.initials: D
authors.lastname: DiLibero
authors.forename: Robert
authors.initials: R
authors.lastname: Willix
authors.forename: Ernst R
authors.initials: ER
authors.lastname: Schwarz
mesh_terms: D004333:Drug Administration Routes; D016903:Drug Monitoring; D006333:Heart Failure / Q000097:blood / Q000378:metabolism / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
chemical_list: D013739:Testosterone